10-Q: Intelligent Bio Solutions Reports Q3 2025 Results, Cites Revenue Dip but Gross Profit Improvement

Intelligent Bio Solutions reports a decrease in revenue for Q3 2025 but highlights an improved gross profit margin driven by strategic sales mix and operational streamlining.

Summary

• Intelligent Bio Solutions Inc. reported a net loss of $2.55 million for the three months ended March 31, 2025, compared to a net loss of $2.99 million for the same period in 2024.
• Revenue decreased to $728,867 from $823,800 year-over-year, primarily due to instability in the construction sector affecting reader sales.
• However, gross profit increased to $341,368 from $178,489, driven by a higher proportion of high-margin cartridge sales and enhanced production capacity.
• Government support income increased to $173,271 from $83,842, reflecting investments in qualifying research and development expenditures.
• Selling, general, and administrative expenses decreased slightly to $2.41 million from $2.43 million.
• Development and regulatory approval expenses decreased to $358,351 from $471,313.
• The company raised approximately $1.49 million through an At The Market (ATM) offering and $2.65 million through a February offering.
• The company acknowledges a material risk that its current cash and cash equivalents of $2.81 million may be insufficient to fund its operating plan for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• The company is working to remediate material weaknesses in internal control over financial reporting.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to decreased revenue and concerns about the company's ability to continue as a going concern, despite improvements in gross profit and successful capital raising efforts. The material weaknesses in internal controls also contribute to the negative sentiment.

Positives

• Gross profit margin improved due to a strategic shift towards higher-margin cartridge sales and enhanced production efficiency.
• Government support income increased, reflecting investments in research and development.
• Selling, general, and administrative expenses decreased slightly.
• The company successfully raised capital through ATM and February offerings.
• The company secured 35 new accounts throughout the quarter ended March 31, 2025, bringing total active customer accounts to over 450 in 24 countries.
• The company announced it had integrated Arabic as the second international language to its Intelligent Fingerprinting Drug Screening System as part of the Company's multilingual upgrade.
• The Company announced it had been granted patent in the United States relating to its Intelligent Fingerprinting Drug Screening Cartridge, marking its sixth patent.

Negatives

• Revenue decreased due to instability in the construction sector affecting reader sales.
• The company reported a net loss of $2.55 million for the quarter.
• The company acknowledges a material risk that its current cash and cash equivalents may be insufficient to fund its operating plan for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• The company identified material weaknesses in internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• Delays in finalizing licensing arrangements related to the Biosensor Platform Technology (BPT) could negatively impact its development and commercialization.
• The company may be required to refund certain amounts from the Australian government grant due to not achieving certain milestones by the prescribed deadline.
• Material weaknesses in internal control over financial reporting could affect the reliability of financial reporting.

Future Outlook

The company anticipates operating losses for the foreseeable future and will need to raise additional funds during the next 12 months to fund its operating plan.

Management Comments

• The company continues to improve on its strategic sales mix and operational streamlining thus driving the increased gross profit as noted above.

Industry Context

The decrease in revenue is attributed to instability in the construction sector, which impacts the demand for the company's reader products used in safety-critical industries.

Comparison to Industry Standards

• It is difficult to compare Intelligent Bio Solutions directly to industry standards without knowing the specific peer group and market segments.
• However, the company's focus on high-margin cartridge sales aligns with a common strategy in the diagnostics industry to generate recurring revenue.
• The company's efforts to obtain regulatory approval in the United States are critical for expanding its market reach and competing with established players in the drug screening market.
• Comparable companies in the point-of-care diagnostics space include Abbott Laboratories, Roche Diagnostics, and QuidelOrtho, but these companies are significantly larger and have more diversified product portfolios.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees face uncertainty due to the company's going concern status.
• Customers may be concerned about the company's long-term viability.
• Creditors face increased risk due to the company's financial challenges.

Next Steps

• The company will continue to pursue regulatory approval in the United States.
• The company will continue to work to finalize licensing arrangements related to the Biosensor Platform Technology (BPT).
• The company will continue to take measures to remediate the material weaknesses in internal control over financial reporting.

Key Dates

Keywords

financial results, quarterly report, revenue, gross profit, net loss, going concern, capital raise, drug screening, biosensor, internal controls